FibroGen Inc (FGEN)
0.39
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 11:27
FibroGen Revenue (Quarterly): 46.33M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 46.33M |
| June 30, 2024 | 50.64M |
| March 31, 2024 | 55.90M |
| December 31, 2023 | 27.14M |
| September 30, 2023 | 40.13M |
| June 30, 2023 | 44.32M |
| March 31, 2023 | 36.16M |
| December 31, 2022 | 34.37M |
| September 30, 2022 | 15.74M |
| June 30, 2022 | 29.81M |
| March 31, 2022 | 60.83M |
| December 31, 2021 | 16.54M |
| September 30, 2021 | 155.97M |
| June 30, 2021 | 24.36M |
| March 31, 2021 | 38.43M |
| December 31, 2020 | 65.00M |
| September 30, 2020 | 44.03M |
| June 30, 2020 | 42.89M |
| March 31, 2020 | 24.40M |
| December 31, 2019 | 7.974M |
| September 30, 2019 | 33.17M |
| June 30, 2019 | 191.57M |
| March 31, 2019 | 23.86M |
| Date | Value |
|---|---|
| December 31, 2018 | 108.06M |
| September 30, 2018 | 29.03M |
| June 30, 2018 | 43.95M |
| March 31, 2018 | 31.92M |
| December 31, 2017 | 30.74M |
| September 30, 2017 | 40.55M |
| June 30, 2017 | 30.27M |
| March 31, 2017 | 29.44M |
| December 31, 2016 | 35.52M |
| September 30, 2016 | 30.10M |
| June 30, 2016 | 89.28M |
| March 31, 2016 | 28.28M |
| December 31, 2015 | 24.44M |
| September 30, 2015 | 19.54M |
| June 30, 2015 | 120.55M |
| March 31, 2015 | 16.30M |
| December 31, 2014 | 16.10M |
| September 30, 2014 | 13.66M |
| June 30, 2014 | 89.96M |
| March 31, 2014 | 17.88M |
| December 31, 2013 | 12.39M |
| September 30, 2013 | 71.25M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.974M
Minimum
Dec 2019
155.97M
Maximum
Sep 2021
43.05M
Average
39.28M
Median
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Arbutus Biopharma Corp | 1.339M |
| GlycoMimetics Inc | -- |
| Cidara Therapeutics Inc | -- |
| Cue Biopharma Inc | 3.336M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.08M |
| Total Expenses (Quarterly) | 44.56M |
| EPS Diluted (Quarterly) | -0.17 |
| Enterprise Value | 22.76M |
| Gross Profit Margin (Quarterly) | 88.57% |
| Profit Margin (Quarterly) | -36.87% |
| Earnings Yield | -315.4% |
| Normalized Earnings Yield | -277.99 |